Global Thrombocytopenia Epidemiology Forecast Report 2018-2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Thrombocytopenia – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP), Prevalent Cases of Immune Thrombocytopenia (ITP), Prevalent Cases of Thrombocytopenia in Chronic Liver Disease, Incident Cases of Chemotherapy-induced Thrombocytopenia, Number of Cases of Heparin-induced Thrombocytopenia and Total Cases of Thrombocytopenia scenario of Thrombocytopenia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.
Thrombocytopenia Detailed Epidemiology Segmentation
- As per the analysis, the total number of cases of Thrombocytopenia in the 7MM was 1,653,934 in 2020. These cases of Thrombocytopenia in the 7MM are expected to increase throughout the study period i.e. 2018-2030, with CAGR of 0.66% for the study period 2018-2030.
- As per the analysis, the United States accounted for the highest number of Thrombocytopenia cases among the 7MM. The total number of Thrombocytopenia cases in the US was estimated to be 467,078 in 2020.
- In 2020, the prevalent population of Thrombotic Thrombocytopenia in the United States was 6,002 which are expected to rise with the CAGR of 0.79% for the study period 2018-2030.
- In 2020, there were 66,708 prevalent cases of Immune thrombocytopenia (ITP) in the United States.
- Germany ranked second-highest for Thrombocytopenia cases among 7MM. In 2020, Germany had 325,202 Thrombocytopenia cases.
- Among the European 5 countries, Germany had the highest cases of Thrombocytopenia with 325,202 cases, followed by the United Kingdom and Spain, with 230,597 cases and 182,796 cases, respectively. On the other hand, Italy had the lowest cases, i.e., 102,933 in 2020.
- As per the analysis, Japan accounted for the fourth-highest number of Thrombocytopenia cases among the 7MM. The total number of Thrombocytopenia cases in Japan was estimated to be 219,017 in 2020.
Scope of the Report
- The report covers the descriptive overview of Thrombocytopenia, explaining its causes, symptoms, and diagnosis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden.
- The report provides the segmentation of the disease epidemiology for 7MM by Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP), Prevalent Cases of Immune Thrombocytopenia (ITP), Prevalent Cases of Thrombocytopenia in Chronic Liver Disease, Incident Cases of Chemotherapy-induced Thrombocytopenia, Number of Cases of Heparin-induced Thrombocytopenia, and Total Cases of Thrombocytopenia.
Report Highlights
- 10-Year Forecast of Thrombocytopenia
- 7MM Coverage
- Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP)
- Prevalent Cases of Immune Thrombocytopenia (ITP)
- Prevalent Cases of Thrombocytopenia in Chronic Liver Disease
- Incident Cases of Chemotherapy-induced Thrombocytopenia
- Number of Cases of Heparin-induced Thrombocytopenia
- Total Cases of Thrombocytopenia
Key Questions Answered
- What are the disease risk, burden, and unmet needs of Thrombocytopenia?
- What is the historical Thrombocytopenia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Thrombocytopenia at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Thrombocytopenia?
- Out of the countries mentioned above, which country would have the highest patient population of Thrombocytopenia during the forecast period (2021-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2018-2030
Key Topics Covered:
1 Key Insights
2 Executive Summary of Thrombocytopenia
3 Thrombocytopenia Epidemiology Overview at a Glance
3.1. Epidemiology Share (%) Distribution of Thrombocytopenia in 2018
3.2. Epidemiology Share (%) Distribution of Thrombocytopenia in 2030
4 Thrombocytopenia: Disease Background and Overview
4.1. Introduction
4.2. Causes of Thrombocytopenia
4.2.1. Emergent Thrombocytopenia
4.2.2. Non-emergent Thrombocytopenia
4.3. Symptoms of Thrombocytopenia
4.4. Diagnosis of Thrombocytopenia
4.4.1. Chemotherapy-induced thrombocytopenia (CIT)
4.4.2. Immune thrombocytopenic purpura
4.4.3. Heparin-induced Thrombocytopenia
4.4.4. Thrombocytopenia associated with Chronic Liver
4.4.5. Thrombotic thrombocytopenic purpura
4.5. Diagnostic Guidelines of Thrombocytopenia
4.5.1. Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
4.5.2. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura (TTP)
4.5.3. Guidelines on the diagnosis of heparin-induced thrombocytopenia (HIT): second edition
5 Epidemiology and Patient Population
5.1. Key Findings
5.2. Epidemiology Methodology
5.3. 7MM Total Prevalent Patient Population of Thrombocytopenia
6 Country Wise-Epidemiology of Thrombocytopenia
6.1 United States Epidemiology
6.2 EU5 Epidemiology
6.2.1 Germany
6.2.2 France
6.2.3 Italy
6.2.4 Spain
6.2.5 United Kingdom
6.3 Japan Epidemiology
7 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/bxdo0f
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
